NEO-X-PRIME
DEAD

Serial Number

79396585

Owner

Alligator Bioscience AB

Filing Date

Mar 14, 2024

Add to watchlist:

No watchlists yet
View on USPTO

NEO-X-PRIME Trademark

Serial Number: 79396585

NEO-X-PRIME is a trademark filed by Alligator Bioscience AB on March 14, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Alligator Bioscience AB (10 trademarks)

c/o Medical Patent AB
Alnarp 23053 , SE

Entity Type: 11

Trademark Details

Filing Date

March 14, 2024

Registration Date

Not Registered

Goods & Services

Antibodies and libraries of antibodies for medical and pharmaceutical purposes; antibody formats, bispecific antibody formats, therapeutic antibodies, bispecific antibody formats and bispecific compounds for medical and pharmaceutical purposes; antibody formats, bispecific antibody formats, therapeutic antibodies, bispecific antibody formats and bispecific compounds for immuno-oncological applications; immuno-oncology preparations for medical and pharmaceutical purposes; antibodies; none of the aforesaid goods being for use in newborn screening and invitro.

Antibodies [for scientific and immuno-oncological use]; libraries and collections of antibodies; antibody formats; bispecific antibody formats, therapeutic antibodies; bispecific antibody formats for immuno-oncological applications; bispecific compounds; none of the aforesaid goods being for use in newborn screening and invitro.

Bio-technology and scientific research services relating to antibodies, antibody formats, bispecific antibody formats, therapeutic antibodies, and immune-oncology preparations; biochemical research and development in the field of antibodies, protein and enzyme; scientific laboratory services relating to antibodies, protein and enzyme; research, production and development services relating to antibody formats, bispecific antibody formats, therapeutic antibodies, bispecific antibody formats and bispecific compounds; research, development and production of immuno-oncology antibody preparations and pharmaceuticals; information, advisory and consultancy services relating to all of the aforesaid services; none of the aforesaid goods being for use in newborn screening and invitro.

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 7, 2026 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Apr 21, 2026 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 21, 2026 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 15, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 29, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 29, 2025 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Apr 21, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 21, 2025 ABN2
REFUSAL PROCESSED BY IB
Oct 19, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 2, 2024 RFCS
REFUSAL PROCESSED BY MPU
Oct 2, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 27, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 26, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 24, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 1, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 1, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 30, 2024 REPR